Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis

2021 ◽  
Author(s):  
Kazumitsu Aoki ◽  
Satoru Matsunaga ◽  
Shinichirou Ito ◽  
Takahiko Shibahara ◽  
Takeshi Nomura ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Necrotic Bone ◽  
Osteonecrosis Of Jaw

scholarly journals Bisphosphonates in the treatment of metabolic bone diseases

2010 ◽  
Vol 54 (2) ◽  
pp. 206-212 ◽  
Author(s):  
Henrique Pierotti Arantes ◽  
André Gonçalves da Silva ◽  
Marise Lazaretti-Castro
Keyword(s):  
Bone Resorption ◽  
Bone Diseases ◽  
Low Bone Mass ◽  
Metabolic Bone Diseases ◽  
Treatment Of Osteoporosis ◽  
Good Safety Profile ◽  
Metabolic Bone ◽  
Prevention And Treatment ◽  
High Bone ◽  
Osteonecrosis Of Jaw

Osteoporosis is a disease characterized by low bone mass associated with the deterioration of microarchitecture, due to an imbalance either in high bone resorption or low bone formation or in both, leading to a high risk of fractures. Bisphosphonates are medications which reduce the ability of osteoclasts to induce bone resorption and consequently improve the balance between resorption and formation. There are bisphosphonates approved for the prevention and treatment of osteoporosis. Administration can be oral (daily, weekly or monthly) or intravenous (quarterly or yearly). These medications are well tolerated and with the correct instructions of administration have a good safety profile. Serious side effects, such as, osteonecrosis of jaw is very rare. Bisphosphonates are the most prescribed medication for the treatment of osteoporosis.

scholarly journals Jaw Osteonecrosis a Risk Factor in Bisphosphonate Therapy - A Dental Concern

2010 ◽  
Vol 4 (3) ◽  
pp. 72-77
Author(s):  
Manpreet S Walia ◽  
Saryu Arora ◽  
Bhawana Singal
Keyword(s):  
Bone Pain ◽  
Bisphosphonate Therapy ◽  
Necrotic Bone ◽  
Preventive Dental Care ◽  
Osteonecrosis Of The Jaws ◽  
Surgical Measures ◽  
Primary Mechanism ◽  
Skeletal Disorders ◽  
Osteonecrosis Of Jaw ◽  
Turn Over

ABSTRACT Bisphosphonates are compound used in the treatment of many skeletal disorders such as bone metastases, osteoporosis, Paget's disease, hypercalcaemia of malignancy and bone pain. A new complication of bisphosphonate therapy administration i.e. osteonecrosis of jaw also known as bisphosphonate related osteonecrosis of the jaws seems to be developing. Over suppression of bone turn over is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. Complete prevention of this complication is not currently possible. However, preventive dental care reduces this incidence. Conservative debridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition.

Co-purification of bone resorbing activity and adenylate cyclase stimulating activity from human tumours associated with the humoral hypercalcaemia of malignancy

1987 ◽  
Vol 114 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Chohei Shigeno ◽  
Itsuo Yamamoto ◽  
Shegiharu Dokoh ◽  
Megumu Hino ◽  
Jun Aoki ◽  
...  
Keyword(s):  
Bone Resorption ◽  
High Performance ◽  
Basic Protein ◽  
Gel Filtration ◽  
Exchange Chromatography ◽  
Protein Factor ◽  
Human Tumours ◽  
Acid Stable ◽  
Bone Resorbing Activity

Abstract. We have partially purified a tumour factor capable of stimulating both bone resorption in vitro and cAMP accumulation in osteoblastic ROS 17/2 cells from three human tumours associated with humoral hypercalcaemia of malignancy. Purification of tumour factor by sequential acid urea extraction, gel filtration and cation-exchange chromatography, reverse-phase high performance liquid chromatography followed by analytical isoelectric focussing provided a basic protein (pI > 9.3) with a molecular weight of approximately 13 000 as a major component of the final preparation which retained both the two bioactivities. Bone resorbing activity and cAMP-increasing activity in purified factor correlated with each other. cAMP-increasing activity of the factor was heat- and acid-stable, but sensitive to alkaline ambient pH. Treatment with trypsin destroyed cAMP-increasing activity of the factor. Synthetic parathyroid hormone (PTH) antagonist, human PTH-(3– 34) completely inhibited the cAMP-increasing activity of the factor. The results suggest that this protein factor, having its effects on both osteoclastic and osteoblastic functions, may be involved in development of enhanced bone resorption in some patients with humoral hypercalcaemia of malignancy.

Polyunsaturated fatty acids and phytoestrogens modulate osteoclastogenesis and bone resorption in raw 264.7 macrophages

2013 ◽  
Author(s):  
Natalie Shepherd ◽  
Jager Cassandre De ◽  
Abe Kasonga ◽  
Sumari Marais ◽  
Yuko Tousen ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Bone Resorption ◽  
Polyunsaturated Fatty Acids ◽  
Raw 264.7 ◽  
Raw 264.7 Macrophages
Sign in / Sign up

Export Citation Format

Share Document